TSL.L Regulatory News (TSL)

18 Jan 2006 12:37

Tissue Science Laboratories PLC18 January 2006 18 January, 2006 Tissue Science Laboratories plc ('TSL' or 'the Company') Tissue Science Laboratories plc (LSE: TSL), the medical devices companyspecialising in human tissue replacement and repair products derived fromporcine dermis, announced that the following Directors purchased ordinary sharespursuant to the Save As You Earn Scheme 2002 ("SAYE SCHEME"): Director Number of Shares Price per shareMartin Hunt, Chief Executive 7,966 93pDavid Jennings, Finance Director 4,796 93p These shares will rank pari passu with the existing class of ordinary 10pshares. Following the inclusion of these shares, the total number of ordinary shares inissue (excluding shares held as treasury shares) is 29,481,645. -Ends-Enquiries: TSL plc Tel: 01252 369603Martin Hunt, Chief ExecutiveDavid Jennings, Finance Director Hogarth Partnership Limited Tel: 020 7357 9477Melanie Toyne-Sewell / Fionnuala Synnott Mob: 07767 66 00 40 Notes to Editors Background on TSL Founded in 1995, with headquarters in Aldershot, Hampshire, TSL is a medicaltechnology company specialising in tissue repair and replacement with aproprietary sheet product, derived from porcine dermis, called Permacol(R). TSLhas launched successfully different formulations of the product and built adevelopment pipeline that addresses the large and fast growing surgical implantmarket. The Company floated in November 2001 and is listed on the AlternativeInvestment Market (LSE: TSL). TSL has a family of products based on the same core technology. Each producthas been adapted, with unique properties, to make it suitable for use indifferent applications, including urology/gynaecology, complex and recurrenthernia repair, shoulder rotator cuff repair and head and face repair andreconstruction. The Company has signed distribution agreements with CR Bard Inc(urology/gynaecology - worldwide), Zimmer Inc (orthopaedic - worldwide) andPorex Surgical Inc (head & face-US and Canada). Further variations of the sheetand injectable forms of Permacol(R) are being developed. Background on Permacol(R)Permacol(R) was developed at Dundee University over a 20 year time period andhas been patented worldwide. The key to the Permacol(R) concept lies in itscollagen Technology which uses non-reconstituted porcine dermal collagen, verysimilar in structure to human tissue. Non-collagenous material, except elastin,is removed by the TSL manufacturing process. The remaining collagen, whichretains its original 3-D structural architecture, is stabilised by a patentedcross-linking process. The result is a non-reconstituted, non-allergenic,collagen implant which is resistant to biodegradation attack, is recognised andaccepted by the body, and is able to provide a long-term support for thein-growth of new tissue and its associated blood supply. This information is provided by RNS The company news service from the London Stock Exchange